Glucagon receptor

This page, as it appeared on June 20, 2016, was featured in this article in the journal Biochemistry and Molecular Biology Education.

Glucagon G protein-coupled receptor

spinqualitylabelsall models Structure of the Class B Human Glucagon G Protein Coupled Receptor-PDB 4L6R Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Class B GPCRs G protein-coupled receptors (GPCRs) are the largest class of integral membrane proteins. GPCRs are divided into five families; the rhodopsin family (class A), the secretin family (class B), the glutamate family (class C), the frizzled/taste family (class F), and the adhesion family. Roughly 5% of the human genome encodes g protein-coupled receptors, which are responsible for the transduction of endogenous signals and the instigation of cellular responses. All GPCRs contain a similar seven α-helical transmembrane domain (TMD or 7TMD) that once bound to its ligand, undergoes a conformational change and tranduces a signal to coupled, heterotrimeric G proteins. The initiation of intracellular signal pathways occur in response to stimuli such as light, Ca2+, amino acids, nucleotides, odorants, peptides, and other proteins, and accomplishes many interesting physiological roles. The human glucagon receptor (GCGR) is one of 15 secretin-like, or Class B, G-protein coupled receptors (GPCRs). Like other GPCRs, it has a 7 trans-membrane helical domain and a globular N-terminus extracellular domain (ECD). Figure 1: Snake Plot of GCGR TMD. Residues of particular importance in glucagon binding affinity are found in green, yellow, and black. Residues in red are the location of critical disulfide bonds, while blue residues were found to be highly conserved across all class B GPCRs. Class B GPCRs contain 15 distinct receptors for peptide hormones and generate their signal pathway through the activation of adenylate cyclase (AC) which increases the intracellular concentration of cAMP, inositol phosphate, and calcium levels. These secondary messengers are essential elements of intracellular signal cascades for human diseases including type II diabetes mellitus, osteoporosis, obesity, cancer, neurological degeneration, cardiovascular diseases, headaches, and psychiatric disorders; making their regulation through drug targeting of particular interest as disease targets. Structural approaches to the development of agonists and antagonists have however been hampered by the lack of accurate Class B TMD visualizations. Recent crystal structures of corticoptropin-releasing factor receptor 1 (PDB: 4K5Y) and human glucagon receptor (PDB: 4L6R) provide a comparison to more well-studied class A GPCRs. Structures of Class A vs. Class B GPCRs Class A and class B glucagon receptors share less than fifteen percent sequence homology, but both share a 7TM domain. Comparison of the class B 7TM helices to that of the class A 7TM helices showed that the general orientation and positioning of the alpha helices are conserved through both classes. Detailed structural alignments of the two GPCR subclasses revealed deviations in the transmembrane region. For instance, the N-terminal end of helix one in class B GCGR is longer than any known class A GPCR structure and stretches three supplementary helical turns above the extracellular (EC) membrane boundary. This region is referred to as the stalk. The stalk is involved in glucagon binding and helps in defining the orientation of the ECD with respect to the 7TM domain. Also specific to class B GPCRs, a Gly residue at position 393 induces a bend in helix VII; this bend is stabilized by the hydrophobic interaction between the glycine 393 and phenylalanine 184. One of the most distinguishable characteristics of the class B 7TM is the helix VIII tilt of 25 degrees and its length compared to that of class A helix VIII tilt, which is much shorter. This helical tilt results from Glu 406 in helix VIII that is fully conserved in secretin-like receptors and forms two interhelical salt bridges with conserved residues Arg 173 and Arg 346. Despite these differences, a vital region that is conserved in both class B and class A receptors is the disulfide bond between Cys 294 and Cys 224 in extracellular loop two (ECL2). This bond stabilizes the receptors entire 7TM fold. Lastly, the locations of the extracellular tips for class B glucagon receptors allow for a much wider and deeper ligand-binding pocket than any of the class A GPCRs. While interfacial interactions are not unique to class B receptors, part of the interface stabilization between helices VI, V, and III includes a Class B-specific hydrogen bond between Asn 318 of Helix V and Leu 242 of Helix III. How These Structures Lead to Function Figure 2: Open conformation in contrast to the closed conformation. The movement of the single helix over the top of the transmembrane domain is the most distinguishable characteristic between closed and open conformation. The stalk is not accessible to glucagon in the closed conformation. Structurally, the 7TM and its signature seven helical structure is involved in signaling via coupling to heterotrimeric G proteins that activate adenylate cyclase to increase the levels of intracellular cyclic AMP. Additionally, this coupling increases levels of IP3 and intracellular calcium levels. The wider and deeper ligand-binding pocket of class B GPCRs allows for a vast array of molecules to be bound that in turn allow for numerous functions activated by peptide receptors. The conformation and orientation of the 7TM and the ECD regions dictate the functionality of the class B G protein-coupled receptor, which has an open and closed conformation of the GCGR (Figure 2). The open conformation is when glucagon can bind to GCGR; in the closed conformation binding does not occur. Glucagon Receptor (GCGR) The glucagon class B GPCR (GCGR) is involved in glucose homeostasis through the binding of the signal peptide glucagon. Glucagon is released from pancreatic α-cells when blood glucose levels fall after a period of fasting or several hours following intake of dietary carbohydrates. Once the peptide hormone is released, it binds to GCGR, a 485 amino acid protein found in the liver, kidney, intestinal smooth muscle, brain, and adipose tissues. Upon binding, signaling is initiated to heterotrimeric G-proteins containing Gαs. GCGR can regulate additional signal pathways, including G-proteins of the Gαi family through the adoption of differing receptor conformations. Glucagon's main role is the regulation of blood glucose levels. Glucagon lowers the concentration of fructose 2,6-bisphosphate, which is an allosteric inhibitor of the gluconeogenic enzyme fructose 1,6-bisphosphotase and activates phosphofructose kinase 1, which increases glucose levels via glycolysis. Glucagon is also a regulator of the production of cholesterol, which is an energetically intensive process. When energy resources are low, downregulation of cholesterol production begins with glucagon binding to GCGR, which stimulates the phosphorylation of HMG-CoA. HMG-CoA is inactivated by phosphorylation and moderates cholesterol production to conserve energy. Glucagon also takes part in fatty acid mobilization by affecting levels of adipose tissue in the organism. Activation of GCGR by glucagon initiates triacylglycerol breakdown and the phosphorylation of perilipin and lipases via cAMP signal pathways. This allows the body to export fatty acids to the liver and other crucial tissues for energy use and makes more glucose available for use in brain functioning. GCGR-Specific Traits Helix I Stalk Region The tip of Helix I extends above the cell membrane into the extracellular space creating a stalk region. This region is longer than any other class of GPCR and extends three α-helical turns above the plane of the membrane. The stalk is proposed to capture the glucagon peptide and to facilitate insertion of the glucagon peptide into the 7tm. Intracellular Helix VIII The GCGR also contains an intracellular Helix VIII that is comprised of roughly 20 amino acids at the C-terminal end. This helix tilts approximately 25 degrees away from the membrane - the corresponding position in class A receptors are turned toward the membrane. This helix is completely conserved in class B structures. Binding Pocket Figure 3. GCGR Binding Pocket. A cross-section of the GCGR binding pocket shows its width and depth. The class B GPCR has the widest and longest binding pocket of all other classes of GPCRs. The distance between the EC tips of Helices II and VI and between the tips of Helices III and VII are some of the largest among the GPCRs. As a result, the binding cavity of GCGR is located deeper inside the receptor, meaning glucagon binds much closer to the cell membrane. Other Unique Structural Features An important interface stabilization interaction between Helices I and VII occurs between Ser 152 of Helix I and Ser 390 of Helix VII. Due to their close proximity to one another, they form an important hydrogen bond which stabilizes the structure of GCGR. Mutations to the homologous residues Ser 135 and Ser 392 alters receptor signaling in glucagon-like peptide-1 receptor (GLP1R). Glucagon Binding The large, soluble N-terminal extracellular domains (ECD) of GCGR provide initial ligand selectivity with the deep, ligand pocket of the TMD providing secondary recognition. Figure 4. Bound Molecule of Glucagon. A molecule of glucagon is shown bound to the GCGR's ECD (shown in magenta) The active, or open conformation, is characterized by an intracellular outward movement of helicies V and VI (breaking hydrogen bonds between Arg173-Ser350 and Glu245-Thr351) and an extracellular rotation of the ECD until it is almost perpendicular to the membrane surface. While the stalk region of Helix I helps to facilitate the motion of the ECD, intracellular G-protein coupling and extracellular glucagon binding stabilized this active state. In the abscence of glucagon, however, the GCGR adopts a closed conformation in which all three of the extracellular loops of the 7tm (ECL1, ECL2, and ECL3) can interact with the ECD. In this closed state, the ECD covers the extracellular surface of the 7tm. To transition between states, the ECD rotates and moves down towards the 7tm domain. This transition mechanism is consistent with the "two-domain" binding mechanism of class B GCPRs in which (1) the C-terminus of the ligand first binds to the ECD allowing (2) the N-terminus of the ligand to interact with the 7tm and activate the protein.​ The residues in the binding pocket that are in direct contact with the glucagon molecule are polar or are hydrophobic. The N-terminus of glucagon binds partly with the ECD while the rest of glucagon binds deep into the binding pocket. The amino acids at the N-terminus of the class B 7TM have the ability to form hydrogen bonds and ionic interactions, which can be seen in the amino acid sequence of glucagon (Figure 5). Figure 5: Structure of Glucagon: The side chains of the residues making up glucagon are depicted. Coloration on the side chains indicate certain atoms that determine the properties the residues hold. The blue indicates a nitrogen atom (hydrophilic properties), the green on the side chains indicates carbon atoms (non-polar hydrophobic properties), and the red coloration indicates an oxygen atom (hydrophilic properties). PDB 1GCN GCGR regions providing binding affinity for glucagon include the α-helical structure of the stalk. The α-helical structure of the stalk interacts directly with glucagon, as it extends nearly three helical turns above the membrane. When the alpha helix of the stalk is disrupted, the affinity of glucagon for GCGR decreases with an alanine 135 to proline substitution having significantly lower affinity for glucagon. The high affinity conformation of GCGR is the open conformation, when glucagon can bind (Figure 2). The disulfide bond between Cys 294 and Cys 224 serves to hold the helices in the proper orientation for binding and stabilizes the open conformation. Additionally, the salt bridges between Glu 406, Arg 173, and Arg 346 hold the open conformation together for higher affinity. Mutagenesis and photo cross-linking studies determined essential, conserved residues in glucagon and have been labeled and colored in red. Glucagon residues His 1, Gln 3, Phe 6, and Tyr 10 are critical to successful binding interaction with the GCGR while others are important for structural rigidity. The n-terminus of glucagon (Figure 5) leads to a protuberance that fits into the deep, interior cavity of the GCGR 7TMD (Figure 3) where four residues reside that play strong roles in ligand binding affinity. There is a narrow neck to the entrance of the cavity, providing a firm anchor during peptide docking (Figure 3). Glucagon Signaling Pathway Glucagon binds to the open conformation of GCGR on the plasma membrane. Glucagon binding to GCGR induces a conformational change in GCGR. This conformation change induces the active state of the protein (Figure 2). The active state of the protein exchanges a guanosine diphosphate (GDP) for guanosine triphosphate (GTP) that is bound to the alpha subunit. With the GTP in place, the activated alpha subunit dissociates from the heterotrimeric G protein'sbeta and gamma subunits. Following dissociation, the alpha subunit can activate adenylate cyclase. Activated adenylate cyclase, catalyzes the conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). cAMP then serves as a secondary messenger to activate, through allosteric binding, cAMP dependent protein kinase A (PKA). PKA activates via phosphorylation the phosphorylase b kinase. The phosphorylase b kinase phosphorylates glycogen phosphorylase b to convert to the active form, phosphorylase a. Phosphorylase a finally catalyzes the release of glucose-1-phosphate into the bloodstream from glycogen polymers (Figure 6). Figure 6: Metabolic Regulation of Glycogen by Glucagon.Depicted is the visualization of the glucagon signaling pathway through the GCGR. The location of the GCGR, the release of the alpha subunit from the beta and gamma subunits, and the enzyme cascade to result in the releasing of glucose are depicted. Abbreviations for the enzymes in the cascade include- PPK: phosphorylase kinase; PYG b: glycogen phosphorylase b; PYG a: glycogen phosphorylase a. Clinical relevance Because GCGR can interact with multiple types of G protein subfamilies, discovering small molecule inhibitors could lead to a wide range of focused therapies. Blocking conformations that favor interaction with specific G proteins could allow the knockdown of targeted signal pathways. For example, GCGR interacts with inhibitory Gαi proteins that antagonize cAMP production. Finding an agonist for this pathway could be used to treat diabetes mellitus. Current attempts to target the GCGR have however been relatively unsuccessful. Small molecule modulators have been reported with enhanced pharmaceutical regulation, but the progress has been modest. Encouraging results have recently come from Eli Lilly and Company who have been testing a small molecule antagonist of the GCGR (LY2409021) in phase two trials, providing hope for more specific control of diabetes mellitus. In addition to diabetes mellitus, future development of signal bias modulators promise to provide focused therapies for obesity, heart disease, hypertension, and cancer. See Also PSI Structural Biology Database G protein-coupled receptors Linked pages of related receptors (co-featured in BAMBED): GPR40 Lysophosphatidic acid receptor Metabotropic glutamate receptor 5 Neurotensin receptor Proteopedia Resources Glucagon G protein-coupled receptor Category:Glucagon Receptor Butler University Proteopedia Pages Receptor Transmembrane (cell surface) receptors 3D structures of glucagon receptor Updated on 12-March-2023 5ee7 - hGCGR + antagonist - human 7s15 - hGCGR + agonist 4ers - hGCGR + antibody 4lf3 - hGCGR (mutant) + antibody 5xez, 5xf1 – hGCGR/endolysin + antibody 5yqz – hGCGR/endolysin + glucagon peptide 6lmk - hGCGR + guanine nucleotide-binding protein + NB35 + glucagon peptide – Cryo EM 6lml, 7v35 - hGCGR + guanine nucleotide-binding protein + Scfv16 + glucagon peptide – Cryo EM 6whc - hGCGR + guanine nucleotide-binding protein + nanobody + dual-agonist peptide – Cryo EM 6wpw - hGCGR + guanine nucleotide-binding protein + NB35 + glucagon derivative – Cryo EM

Student Contributors

Steven Bennett

Sydney Caskey

Alexis Coulis

Olivia Murfield

Allie Paton

Dean Williams

Proteopedia Page Contributors and Editors (what is this?)

R. Jeremy Johnson, Michal Harel, Karsten Theis, Angel Herraez, Alexander Berchansky, Joel L. Sussman